API | emactuzumab

emactuzumab Report issue

Biologics mAb Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Emactuzumab (RG-7155) is a humanized monoclonal antibody directed against colony stimulating factor 1 receptor (CSF-1R) expressed on macrophages and has demonstrated a profound antitumor effect through interference with the CSF-1/CSF-1R axis, along with a manageable safety profile in patients with diffuse-type tenosynovial giant cell tumors (d-TGCT). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

None

emactuzumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Macrophage colony-stimulating factor 1 receptor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

emactuzumab | rg7155 | rg-7155 | ro5509554 | ro-5509554

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Fallopian Tube Neoplasms (Phase 2)

Hamartoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1/Phase 2)

Tomography (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue